Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.36 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.36 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.36 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.36 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482426 | 0.81 | MTOR (0.41) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL482066 | 0.79 | TLR9 (0.45) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL976246 | 0.77 | ABL1 (0.35) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL974737 | 0.76 | CYP1A2 (0.38) | MTORSMN1; SMN2MAP3K11TLR7GAA | |
| SCHEMBL482137 | 0.76 | CYP1A2 (0.38) | MTORSMN1; SMN2MAP3K11TLR7GAA | |
| SCHEMBL975801 | 0.76 | CYP1A2 (0.38) | MTORSMN1; SMN2MAP3K11TLR7GAA | |
| SCHEMBL976145 | 0.76 | ALOX15 (0.34) | TSHRTBK1CNR2 | |
| SCHEMBL977387 | 0.75 | CYP1A2 (0.49) | MTORSMN1; SMN2MAP3K11TLR7GAA | |
| SCHEMBL978018 | 0.75 | CYP1A2 (0.49) | MTORSMN1; SMN2MAP3K11TLR7GAA | |
| SCHEMBL977388 | 0.75 | CYP1A2 (0.49) | MTORSMN1; SMN2MAP3K11TLR7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2583970-B1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | CYTOKINETICS INC (US) | 2015-10-14 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2995619-B1 | CERTAIN CHEMICAL ENTITIES COMPRISING IMIDAZOPYRIMIDINES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2069352-B9 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2583970-B1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | CYTOKINETICS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-8293761-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | disclosed |
| US-7598248-B2 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210645-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | MTOR 607/4885RICTOR 1531/4885RPTOR 436/4885 |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | MTOR 4448/4885RICTOR 4039/4885RPTOR 2914/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | MTOR 607/4885RICTOR 1531/4885RPTOR 436/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | MTOR 3297/4885RICTOR 2687/4885RPTOR 4781/4885 |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | TNNC1, TNNI3, TNNT2 | MTOR 3118/4885RICTOR 4322/4885RPTOR 1884/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | MTOR 607/4885RICTOR 1531/4885RPTOR 436/4885 |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | MTOR 2781/4885RICTOR 3975/4885RPTOR 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.